Jesper Brandgaard/LinkedIn
Dec 7, 2025, 05:45
Jesper Brandgaard: Novo Nordisk Haemophilia Foundation is Evolving into the Novo Nordisk Haemophilia and Haemoglobinopathies Foundation
Jesper Brandgaard, Chairman at LEO Pharma, posted on LinkedIn:
“As the former President of the Council, I am absolutely delighted to share that the Novo Nordisk Haemophilia Foundation is evolving into the Novo Nordisk Haemophilia and Haemoglobinopathies Foundation. It’s truly inspiring to witness the mission grow to support even more lives. A huge thank you to the Novo Nordisk Foundation for joining as an accelerating partner on this ambitious journey to quadruple the annual beneficiaries by 2030.
Congratulations to the entire NNHF Council and Team – here’s to an exciting new era ahead!”
Get the latest with Hemostasis Today.
-
Sep 9, 2026, 14:48The French Care Pathway for Gene Therapy in Haemophilia B – CRH French Reference Center for Hemophilia Lyon
-
Sep 9, 2026, 14:43David McIntosh: The Ethics of Plasma Donation
-
Sep 9, 2026, 14:42Thirunavukkarasu Angappan: Factor VIII and IX Didn’t Get Viral-Safety Rules Until the 1980s
-
Sep 9, 2026, 14:30Alejandro González Veliz: 2026 ESC Guidelines Expand Cardiac Rehabilitation Beyond Post-Event Recovery
-
Sep 9, 2026, 13:59Natalie Arnold: Biomarkers and the Hidden Burden of CHD
-
Sep 9, 2026, 13:11Ron DePinho: A Negative Trial Does Not Repudiate Inflammation as a Cardiovascular Target
-
Sep 9, 2026, 13:10Ahmad Gharehbaghian: Visiting the Alborz Provincial Blood Transfusion Center
-
Sep 9, 2026, 13:09Oraianthi Fiste: New Collection on Cancer-Associated Thrombosis From Mechanisms to Precision Medicine
-
Sep 9, 2026, 13:07Can Özlü: Can the HALP Score Help Identify Thrombotic Risk in Myeloproliferative Neoplasms?